Alpha-1 antitrypsin deficiency gene therapy (Applied Genetic)

N/A

Report date: 2023/10/26 16:01:45

Base Information

Drug NameAlpha-1 antitrypsin deficiency gene therapy (Applied Genetic)

Drug Alias Nameα-1抗胰蛋白酶缺乏症基因疗法Recombinant AAV-AAT vector gene therapyrAAV1-CB-hAATα-1 antitrypsin deficiency gene therapy (Applied Genetic)AGTC-0106

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV1 vector

Mechanisms of ActionGene transferenceProtease inhibitors

TargetsProtease

Therapy Area/Indicationsalpha 1-Antitrypsin Deficiency

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesIreland

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesApplied Genetic

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive Indicationsalpha 1-Antitrypsin Deficiency

ATC CodeN/A